Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs 2008 Feb;9(2):210-25 PMID: 18246524

Pubmed ID

18246524

Abstract

Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing.

Author List

Peppard WJ, Schuenke CD

Author

William J. Peppard PharmD Trauma/Surgical Critical Care Pharmacist in the Pharmacy department at Froedtert Hospital




Scopus

2-s2.0-38849190721   22 Citations

MESH terms used to index this publication - Major topics in bold

Animals
Anti-Bacterial Agents
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Evaluation, Preclinical
Folic Acid Antagonists
Humans
Methicillin Resistance
Molecular Structure
Patents as Topic
Pyrimidines
Staphylococcal Infections
Structure-Activity Relationship
jenkins-FCD Prod-300 626508253d14e4184314fb9f66322a03a5906796